Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models. (Q39324719)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

title

Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Gregory S Vosganian

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

Rinke Bos

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

publication date

1 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

published in

Journal of Immunotherapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

473-477

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

6 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

Resistance to BRAF Inhibition in Melanomas

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

CD4 T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8 T lymphocytes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485086

The Fate of Low Affinity Tumor-Specific CD8 T Cells in Tumor-Bearing Mice

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22735805

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tumor-Specific CD4 T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8 T Cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22735805

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/CJI.0B013E3182618209

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22735805 AND SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

22735805

1 reference